Evidence map›Paper›PMID 41704810›Full record

ArticleContemporary clinical trials communications2026

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

Domenica M Rubino, Vicki Mooney, Viviënne van de Walle, David Baanstra, Wouter Daniëls, Christopher Recaldin, Joe Nadglowski

Abstract read
In one paragraph

Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Domenica M RubinoWashington Center for Weight Management and Research, Arlington, VA, USA.
Vicki MooneyEuropean Coalition for People Living with Obesity, Dublin, Ireland.
Viviënne van de WallePT&R, Born, the Netherlands.
David BaanstraBoehringer Ingelheim B.V., Amsterdam, the Netherlands.
Wouter DaniëlsBoehringer Ingelheim B.V., Amsterdam, the Netherlands.
Christopher RecaldinBranding Science, London, UK.
Joe NadglowskiObesity Action Coalition, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Clinical trial simulations (CTSs) are an increasingly common way to incorporate site staff and participant feedback into clinical trial design. CTSs can help overcome the unique challenges presented in obesity trials. Here, a CTS was conducted for three trials from the SYNCHRONIZE™ phase 3 program of survodutide in obesity. Methods: Individuals meeting the inclusion criteria of the SYNCHRONIZE trials (referred to as "participants"), and clinical trial professionals with experience in conducting obesity trials ("site staff"), were recruited. Trial designs were reviewed by participants and site staff, and participant-facing materials by participants. Both groups were interviewed about these aspects of the trials. Results: Overall responses to the clinical trial designs were positive. Site staff were comfortable with the inclusion/exclusion criteria and thought recruitment would not be difficult. However, they indicated that pre-screening could help ensure participants' appropriateness for the trial. Additionally, they felt steps should be taken to encourage participant engagement throughout the trial. Participants' concerns focused on optimizing training and educational materials, time commitments for the trial, and burden of data collection. Recommendations from the CTS led to changes in visit interval, increased virtual visit options, and changes in participant materials. Conclusions: These results suggest participant and site staff input from a CTS could help improve obesity clinical trial design, which may ultimately lead to more robust data and reliable clinical findings.

Indexed as

Anti-obesity agentsClinical trial protocolClinical trialsGlucagon-like peptide-1 receptor agonistsGlucagon receptor agonistsObesityOverweight

Identifiers

PMID41704810
PMCPMC12907877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.